New Hair Loss Treatments in Clinical Trials: Clascoterone, Pyrilutamide and What the Published Data Actually Show

Who This Is For#

This guide is for you if:

• You want to know which pipeline drugs have published human data and which do not
• You have read about clascoterone (Breezula) or pyrilutamide (KX-826) and want the primary sources
• You are offered PRP, exosomes or a stem-cell product and want the trial evidence separated from the pitch
• You are deciding whether to wait for something new or treat with what exists

This guide is NOT for you if:

• You want the options available now (see hair loss medications compared and androgenetic alopecia)
• Your hair came out in sudden round patches, a different disease (see alopecia areata and JAK inhibitors for alopecia areata)
• Your scalp is painful, scarred, red or scaling where hair is missing (see scarring alopecia types and when to see a dermatologist promptly)

The Two Names in the Headline, and What Is Actually Published#

The pipeline is crowded, and a 2026 review of the emerging pharmacotherapies concludes that "Ongoing and future clinical trials will determine their definitive role in reshaping the therapeutic landscape of androgenetic alopecia" [10]. A list of candidates is not a list of options.

Clascoterone and pyrilutamide are both topical androgen receptor blockers. Pattern hair loss is driven by androgen signaling in the follicle (see DHT and hair loss), so blocking the receptor at the scalp instead of lowering hormones body-wide is worth testing. The question is what the testing showed.

Clascoterone is a real approved drug, for acne, not for hair#

The label is unambiguous: "WINLEVI (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older" [4]. Its first approval, in August 2020 in the USA, was for clascoterone cream 1% in acne [1]. There is no hair-loss indication on that label [4].

The hair-loss program uses a different product. As the 2020 approval review put it, "Clinical studies of a different formulation of clascoterone (a solution containing a higher concentration of the drug) for the treatment of androgenetic alopecia are underway in Germany and the USA" [1]. A 2019 laboratory paper called the molecule "currently being analyzed in a large phase 2 clinical trial for the topical treatment of androgenetic alopecia (AGA)" [2]. Neither statement is a result.

The one published clinical study of that solution measured cardiac safety, not hair: thirty-two volunteers randomized to the 7.5% clascoterone solution or a matching vehicle, with no effect on the QTc interval in the concentration range tested [3]. It carries one point for a clinician: while little is absorbed from the cream, "the solution formulation developed for the treatment of androgenetic alopecia leads to a measurable systemic concentration and accumulation of the antiandrogen" [3].

So for clascoterone in hair loss, the peer-reviewed record contains no target-area hair count, no sample size, no p-value, no phase 3 publication. Any regrowth percentage quoted elsewhere cannot be traced to the published literature.

Pyrilutamide (KX-826) is named in reviews, with no human results attached#

The pattern repeats. A 2023 review states only that "Pyrilutamide and GT20029 are being studied as topical antagonists of the androgen receptor" [5]. A 2026 review calls it an investigational pharmacotherapy providing "targeted androgen receptor modulation without systemic hormonal suppression" [6] — mechanism, not outcome — while repeating that "rigorous, standardized, and long-term clinical trials are required to establish efficacy" [6].

The only place a pyrilutamide number surfaces is animal work, where it is the benchmark for something else: in a hair-growth mouse model, a new compound at 0.5% "achieved comparable efficacy to 0.5% pyrilutamide with accelerated response kinetics (14-day vs 21-day onset)" [7]. Mice, not men. Pyrilutamide has no approved indication, no product label, and no published paper reporting a phase 2 or phase 3 primary endpoint in humans.

What a Phase 2 Endpoint Is, and Why It Is Not a Treatment#

Trials in pattern hair loss usually measure target-area hair count: a small marked patch of scalp is photographed at baseline and again at a fixed week, and the hairs inside it are counted. The primary endpoint is the change in that number against placebo at a prespecified week — Week 12 in the GT20029 trial [8], week 24 in the topical finasteride phase III [9]. That answers a narrow question, and a positive phase 2 is permission to run a phase 3, not a product.

GT20029 shows exactly what a positive phase 2 looks like#

The clearest published example in this class is GT20029, another topical androgen receptor agent. In a multicenter, randomized, double-blind, placebo-controlled trial, 180 eligible subjects (Hamilton-Norwood IIIv-V) were randomized equally into six groups receiving GT20029 (0.5% or 1.0%) or placebo, either once daily (QD) or twice weekly (BIW) for 12 weeks; the primary endpoint was change in target area non-vellus hair count (TAHC) at Week 12 [8].

The result is genuinely positive and genuinely limited. All four GT20029-treated groups showed significant increases in TAHC at Week 12 (p < 0.001), but only the "0.5% QD and 1.0% BIW groups showing significant improvement over their respective placebo groups (p = 0.032 and p = 0.023)" [8]. Hair width improved significantly in the 1.0% BIW group vs placebo (p = 0.011), adverse events were "similar across all groups and mostly mild," and the authors concluded that "Further studies are warranted to confirm its therapeutic potential in AGA" [8].

Improving from baseline in all four active arms is not the same as beating placebo, and only half the arms did that. One trial, one country, 180 men, 12 weeks, no published phase 3, no approval on file: that is the distance between a headline and a prescription, and the distance clascoterone and pyrilutamide have yet to cross in public (treatment evidence explorer).

New Formulation, Not New Molecule#

Much of what gets marketed as new is an old drug in a different vehicle or by a different route.

Topical finasteride spray has the strongest recent formulation dataset. A phase III, multicenter, randomized, double-blind, placebo-controlled trial enrolled 270 individuals with AGA from 16 sites across China, randomized 2:1 to topical finasteride or placebo once daily for 24 weeks; the primary endpoint was change from baseline in target area (0.903 cm² area) hair count at week 24, and 251 completed the study [9]. That endpoint was met — the change was significantly higher at week 24 (P <0.05) — "although it was only numerically higher at week 12 (P = 0.0688)," and treatment "was generally safe and well-tolerated" [9]. Note the honest detail: at 12 weeks the difference had not reached significance. Patience is part of the data, and the topical finasteride guide covers what to raise with a prescriber.

Minoxidil developments are route and formulation changes, not new pharmacology. A meta-analysis of four RCTs found no difference between oral and topical minoxidil in hair density (SMD 0.02; 95% CI -0.25 to 0.29; P = 0.88), while hypertrichosis was significantly more common with oral minoxidil (RR 2.01; 95% CI 1.18-3.41; P = 0.01) [13]. A systematic review of low-dose oral minoxidil across 19,218 patients reported objective clinical improvement in 61-100% of androgenetic alopecia patients [11] — a proportion improving, not a measured margin over placebo — and hypertrichosis drove 34.6% of discontinuations in a separate low-dose oral minoxidil meta-analysis [12]. Detail belongs in the oral minoxidil review and the minoxidil 5% guide; dose and route are prescriber decisions.

Reformulation questions get answered; new-molecule questions mostly do not#

Ask whether topical finasteride spray beats placebo at 24 weeks and there is a phase III with numbers [9]. Ask whether oral minoxidil beats topical and there is a meta-analysis [13]. Ask how well clascoterone regrows hair and the record is silent. That difference is itself information.

PRP, Exosomes and Stem-Cell Products: Evidence Versus Marketing#

PRP has randomized evidence with a mixed result inside it. A meta-analysis of RCTs included nine trials involving 238 patients [14]. PRP "increased hair density at 3 and 6 months with statistically significant differences compared with the placebo (P < .05)," but "also increased hair count and hair diameter compared with the baseline, but there was no significant difference compared with the placebo (P > .05)" [14]. Density beat placebo; count and diameter did not. Marketing that flattens this into "PRP regrows hair" claims more than the pooled trials support — the PRP guide covers protocols and costs.

Exosome and stem-cell products sit far earlier than their marketing implies. A review of the clinical literature screened 48 studies and found nine clinical studies relevant to alopecia, in which one hundred twenty-five patients received an exosome treatment for hair loss [15]. Side effects were rare there, but "in the broader field of dermatology, at least 10 serious adverse events have been reported" [15]. The authors are direct: "very limited data are available on the safety and efficacy of exosome use in human subjects," and there is demand for "larger well-designed clinical trials" plus "consistent manufacturing standards and regulatory oversight" [15]. A 2025 review still lists exosomes among therapies "being explored" [16].

The gap between exploratory and purchasable#

None of this says exosome therapy cannot work. It says the human evidence here is 125 patients across nine studies [15], and that oversight and manufacturing standards are open problems named by reviewers, not by skeptics [15]. If a clinic quotes a benefit, ask which randomized trial it comes from.

Microneedling Combinations: Old Technique, Reasonable Data#

Microneedling keeps appearing in "new treatment" coverage, and its data are better than most of the pipeline's. A regression synthesis found microneedling monotherapy increased total hair count more than topical minoxidil 5% (β = 12.29; p < 0.001), and that microneedling with topical 5% minoxidil beat microneedling alone (β = 7.63, p < 0.05) [17]. A 2025 systematic review identified 12 RCTs involving 631 AGA patients and pooled 11 of them; combined therapy improved hair count over minoxidil monotherapy (SMD 1.32, 95% CI 0.73-1.92, p < 0.01), with substantial heterogeneity (I² = 88%, p < 0.01) [18].

The pooled effect is real, the protocol behind it is not standardised#

That heterogeneity is the catch: trials used different needle depths, intervals and co-treatments, so the pooled effect averages protocols that are not interchangeable. A broader review says the same of the field — "the quality of evidence varies greatly and there is still a great need for randomized double blinded clinical trials" [19]. Protocol detail is in the microneedling guide.

JAK Inhibitors Are for a Different Disease#

JAK inhibitors appear constantly in hair loss coverage, and they are genuinely effective — for alopecia areata, "an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes" [20], not for pattern loss. The pivotal evidence is two phase 3 trials enrolling 654 patients in BRAVE-AA1 and 546 in BRAVE-AA2, where the estimated percentage of patients reaching a SALT score of 20 or less at week 36 was 38.8% with 4-mg baricitinib, 22.8% with 2-mg baricitinib and 6.2% with placebo in BRAVE-AA1, and 35.9%, 19.4% and 3.3% respectively in BRAVE-AA2 [20].

Strong evidence, wrong disease#

That is a different mechanism from androgen-driven thinning. The published JAK-inhibitor evidence in hair loss is in alopecia areata, not pattern loss, and the 38.8% figure says nothing about a receding hairline. If your loss is patchy and sudden, see a dermatologist and read the JAK inhibitor guide; if it is gradual and patterned, this is the wrong class of drug.

How to Read the Next "Breakthrough" Headline#

Publication, placebo, endpoint, label#

Four questions separate evidence from anticipation: is there a publication, or only an announcement — reviews calling a study ongoing [1][2][5] are not results; did the drug beat placebo, or only baseline [8]; what endpoint, at what week [8][9]; and what does the label say [4]?

If you are losing hair now, your decision concerns established options, timing and diagnosis, not the pipeline. Start with when to start treatment, settle the diagnosis if your pattern is unclear (diffuse thinning vs pattern baldness), and take baseline photographs so whatever you choose can be measured.

Frequently Asked Questions#

Related Resources#

• Androgenetic Alopecia: Complete Guide
• Hair Loss Medications: The Complete Comparison Guide
• Topical Finasteride for Hair Loss: Benefits, How to Apply, and What to Expect
• Oral Minoxidil for Hair Loss: Evidence-Based Review
• PRP for Hair Loss: Complete Treatment Guide
• Microneedling for Hair Loss: How to Do It Right
• JAK Inhibitors for Alopecia Areata
• When to See a Dermatologist for Hair Loss: Red Flags